… discuss the reemergence of the antibody-drug conjugate belantamab and how … landscape now dominated by bispecific antibodies and cellular therapies. Panelists explain … community settings more familiar with antibody drug conjugates. They note ongoing …

Successfully implementing bispecific antibody therapy for follicular lymphoma requires … expand the use of bispecific antibodies while enhancing efficiency, patient experience …

… practical workflows for administering bispecific antibodies in clinical practice. Panelists emphasize …

… observed: the formation of neutralizing antibodies against HIV after a single … called the V3-glycan epitope. Antibodies targeting this region were thought …

… company’s vaccine- alternative monoclonal antibody investigational candidate for the prevention … and tolerability associated with monoclonal antibody-mediated prophylaxis compared to mRNA … to create best in class antibodies. In March 2024, Invivyd received …

… the field: inducing neutralizing antibodies against HIV after a … Conventional wisdom held that antibodies targeting this region required … types of HIV-neutralizing antibodies that target the V3 … glycan region. Type I antibodies represent the previously known …

… syncytial virus (RSV) monoclonal antibody program under a license agreement … maternal immunization and existing preventive antibodies, gaps in protection remain. … infants, while currently available monoclonal antibody products are high-cost interventions …

… has successfully developed a novel antibody that neutralises this protein, … developed a monoclonal antibody that neutralises FABP4. This antibody not only inhibits … Lee said, "This neutralising antibody against FABP4 demonstrates significant potential …

… . The report, titled "Antibody Conjugation Kits Market | Global Market … labeling systems designed for controlled antibody modification. These kits support applications … . Regional Dynamics in the Antibody Conjugation Kits Market Asia Pacific …

… viruses. The dominant antibody in the bloodstream is immunoglobulin G (IgG), which … accounts for about 75 percent of circulating antibodies … the potential to design therapeutic antibodies with customized immune effects. “These …